News

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...
This year, drug companies have been living under a cloud of uncertainty created by the Trump administration. Threats of tough ...
Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...
Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...
The drugmaker's dividend streak is impressive, and the stock is trading at reasonable levels. 10 stocks we like better than ...
Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.
MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The GLP-1 arena has turned into a boxing match between heavyweights Novo Nordisk and Eli Lilly as the two pharma giants ...